Elicio Therapeutics (ELTX) Retained Earnings (2020 - 2026)
Elicio Therapeutics' (ELTX) quarterly Retained Earnings came in at $244.1 million in Q1 2026, up 13.9% YoY from $214.3 million in Q1 2025, and up 192339.37% on a QoQ basis from -$127000.0 in Q4 2025.
Elicio Therapeutics (ELTX) Retained Earnings (2020 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has 7 years of Retained Earnings data on file, last reported at $244.1 million in Q1 2026.
- Quarterly Retained Earnings rose 13.9% year-over-year to $244.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $244.1 million (up 13.9% YoY) and the FY2025 annual result came in at -$127000.0, up 99.93% from the prior year.
- Retained Earnings grew to $244.1 million in Q1 2026, from -$127000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $297.1 million in Q3 2022 to a low of -$238.5 million in Q2 2022.
- A 5-year average of -$49.2 million and a median of -$127.9 million in 2023 frame the typical range for Retained Earnings.
- The widest YoY moves for Retained Earnings: up 96395.76% in 2024, down 98428.43% in 2024.
- Tracing ELTX's Retained Earnings over 5 years: stood at $297.1 million in 2022, then slumped by 100.07% to -$197000.0 in 2023, then sank by 98428.43% to -$194.1 million in 2024, then soared by 99.93% to -$127000.0 in 2025, then surged by 192339.37% to $244.1 million in 2026.
- The last three Retained Earnings figures came in at $244.1 million (Q1 2026), -$127000.0 (Q4 2025), and -$226.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Elicio Therapeutics | 58.41 Mn | 34.91 Mn | - | 261.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 261.71 Mn |
| Mar 31, 2026 | 244.14 Mn |
| Dec 31, 2025 | -127,000.00 |
| Sep 30, 2025 | -225.95 Mn |
| Jun 30, 2025 | -215.90 Mn |
| Mar 31, 2025 | 214.35 Mn |
| Dec 31, 2024 | -194.10 Mn |
| Sep 30, 2024 | -180.10 Mn |
| Jun 30, 2024 | -161.30 Mn |
| Mar 31, 2024 | 159.22 Mn |
| Dec 31, 2023 | -197,000.00 |
| Sep 30, 2023 | -133.25 Mn |
| Jun 30, 2023 | -122.60 Mn |
| Mar 31, 2023 | 165,000.00 |
| Sep 30, 2022 | 297.11 Mn |
| Jun 30, 2022 | -238.51 Mn |
| Mar 31, 2022 | -229.40 Mn |
| Dec 31, 2021 | 296.45 Mn |
| Sep 30, 2021 | -230.03 Mn |
| Jun 30, 2021 | 295.64 Mn |